Soligenix (Nasdaq: SNGX) reported that a small comparative study of synthetic hypericin (HyBryte) versus mechlorethamine (Valchlor) in cutaneous T-cell lymphoma (CTCL) showed a higher treatment success rate and a cleaner tolerability profile for the photodynamic agent, though the sample size was too small to reach statistical significance.
The HPN-CTCL-04 study is a randomized comparability study evaluating HyBryte against Valchlor over 12 weeks in patients with CTCL, measuring response across three to five prospectively identified index lesions per patient.
At 12 weeks, 60% of patients in the HyBryte arm met the pre-specified treatment success threshold — defined as at least a 50% improvement in cumulative mCAILS score from baseline — compared with 20% in the Valchlor arm. Average cumulative mCAILS improvement was 52.5% versus 34.7%, respectively. The results did not achieve statistical significance, which the study's principal investigator, Brian Poligone of the Rochester Skin Lymphoma Medical Group, attributed to the small sample size and a randomization that assigned patients with more extensive disease to the HyBryte arm.
No HyBryte-treated patients experienced a treatment-related adverse event. In the Valchlor arm, 60% of patients had at least one related adverse event — including rashes, application site sensitivity, allergic contact dermatitis, and dermatitis — and one patient was permanently discontinued due to clinically significant allergic contact dermatitis.
The tolerability contrast is the more interpretable signal from a study this size. The efficacy numbers, while directionally consistent with prior HyBryte data, carry limited inferential weight from what appears to be approximately five patients per arm. Cross-trial comparisons are limited by differences in patient populations, study designs, and endpoints, and the HPN-CTCL-04 data should be read as hypothesis-generating rather than confirmatory.
HyBryte works by topical application of synthetic hypericin, a photosensitizer taken up by malignant T-cells in skin lesions and then activated approximately 24 hours later by visible light in the red-yellow spectrum. Because the mechanism does not involve DNA damage and uses visible rather than ultraviolet light, the therapy avoids the secondary malignancy risks associated with UV-based phototherapy, including melanoma, and may reduce the non-melanoma skin cancer risk associated with DNA-alkylating agents such as mechlorethamine.
Approval pathway
Valchlor, the most direct topical comparator, is a nitrogen mustard that covalently alkylates DNA and is approved only for patients who have already failed at least one prior skin-directed therapy. That positioning detail matters for understanding what Soligenix is trying to accomplish. No drug is specifically established as a front-line standard for early-stage CTCL. Every drug currently on the market — Valchlor, bexarotene, vorinostat, romidepsin, mogamulizumab, and the reformulated denileukin diftitox — generally sit later in the treatment sequence, with labels typically requiring prior skin-directed or systemic therapy depending on the agent. If Soligenix can complete a successful confirmatory Phase III trial, HyBryte would enter a regulatory space that no other approved agent currently occupies.
The path to that approval runs through FLASH 2, a randomized, double-blind, placebo-controlled, multicenter study targeting approximately 80 patients with early-stage CTCL. The trial follows a 2023 setback in which the US FDA issued a refusal-to-file letter for HyBryte’s NDA, stating that the application was not sufficiently complete to permit substantive review. Subsequent discussions with the agency indicated that additional clinical data would be required, informing the design of the confirmatory study.
In the first FLASH study, which enrolled 169 patients (166 evaluable) with Stage IA, IB, or IIA disease, 49% of patients who completed all three cycles demonstrated a treatment response (p<0.0001 versus placebo in Cycle 1). The confirmatory study has cleared its first safety review milestone, with a pre-specified blinded interim analysis expected in the second quarter of 2026.
The regulatory picture remains split. FLASH 2 reflects alignment with the EMA, which has accepted a placebo-controlled design similar to the original FLASH study. By contrast, the US FDA has indicated a preference for a longer-duration active comparator trial, and discussions remain ongoing following the earlier refusal-to-file decision. The divergence introduces uncertainty around the US approval pathway specifically.
For a disease affecting roughly 31,000 patients in the US and 38,000 in Europe, with no approved first-line option and treatment decisions heavily influenced by the safety risks of available therapies, the commercial and clinical logic behind a non-genotoxic, topical, visible-light-activated agent is coherent. Whether the Phase III data will support it remains to be seen. The blinded interim analysis from FLASH 2, expected mid-year, will be the next material data point for the program.
Spot something wrong? Report an issue with this article